<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="permitted which does not comply with these terms. Abstract The" exact="influenza" post="A virus infection continues to be a threat to"/>
 <result pre="Abs that play a protective role during infection or vaccination." exact="influenza" post="A virus neutralizing antibodies non-neutralizing antibidies influenza proteins protective"/>
 <result pre="infection or vaccination. influenza A virus neutralizing antibodies non-neutralizing antibidies" exact="influenza" post="proteins protective antibodies Funding Consejo Nacional de Ciencia y"/>
 <result pre="y Tecnología10.13039/501100003141 fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction The" exact="influenza" post="proteins are recognized as foreign by the immune system,"/>
 <result pre="This mechanism makes it necessary the annual revision of seasonal" exact="influenza" post="vaccines. On the contrary, the antigenic shift occurs rarely,"/>
 <result pre="Virus Vaccines Currently, there are three types of licensed human" exact="influenza" post="vaccines: trivalent/quadrivalent inactivated vaccines (TIV/QIV) live attenuated vaccines (LAIV)"/>
 <result pre="are non-adjuvanted inactivated vaccines composed of three or four circulating" exact="influenza" post="virus strains (H1N1, H3N2, B; or two B strains"/>
 <result pre="in the nasal cavities. Flublok is a trivalent recombinant hemmaglutinin" exact="influenza" post="vaccine, licensed by the FDA (US Food and Drug"/>
 <result pre="in 2013, that contains HA antigens derived from the three" exact="influenza" post="virus strains recommended by the World Health Organization (WHO)"/>
 <result pre="Mouse Model The first Abs that participate in clearing an" exact="influenza" post="infection are the so-called natural Abs, which are polyreactive"/>
 <result pre="the antigens (11). The role of natural Abs in the" exact="influenza" post="infection was addressed by Baumgarth et al., who showed"/>
 <result pre="serum from wild-type to IgM KO (−/−) mice infected with" exact="influenza" post="reduced the mortality in comparison to the controls (12)."/>
 <result pre="major promotors of center germinal formation (15, 16). Once the" exact="influenza" post="antigens reach the draining lymph nodes, two types of"/>
 <result pre="responses. Antibodies Against IAV External Proteins HA-Specific Antibodies HA from" exact="influenza" post="viruses is a spike-shaped protein that extends from the"/>
 <result pre="original antigenic sin Most of the classical neutralizing Abs against" exact="influenza" post="are directed to the conformational epitopes on HA, particularly"/>
 <result pre="the hierarchy of immunodominance for the HA of a post-2009" exact="influenza" post="pandemic strain, A/Michigan/45/2015 (H1N1) in several species including humans:"/>
 <result pre="vaccination usually are strain-specific, and they will hardly neutralize subsequent" exact="influenza" post="virus strains (homosubtypic protection). This is explained by the"/>
 <result pre="(antigenic drift) makes it necessary the annual reformulation of seasonal" exact="influenza" post="vaccines. Only specific Abs for the head of HA"/>
 <result pre="by Thomas Francis to describe the fact that in humans," exact="influenza" post="virus infections in childhood leaves an immunological imprint that"/>
 <result pre="with an OAS phenotype were effective in neutralizing antigenically different" exact="influenza" post="virus strains in vivo, indicating that OAS-Abs are an"/>
 <result pre="HCDR3. In this report, CH65 neutralized 30 out of 36" exact="influenza" post="H1N1 strains in vitro (44). Other receptor-binding site mAb"/>
 <result pre="and is capable to neutralize group 1 and group 2" exact="influenza" post="virus strains (45). Furthermore, anti-head broadly neutralizing mAbs whose"/>
 <result pre="group 1 (CR6261), group 2 (CR8020), and both groups of" exact="influenza" post="viruses (FI6) (49–51), have been described in humans. Unfortunately,"/>
 <result pre="al. analyzed the cross-reactivity pattern of anti-HA Abs after an" exact="influenza" post="infection in patients diagnosed with pH1N1/2009 or seasonal H3N2,"/>
 <result pre="HA globular domain prevails with the subsequent encounters with the" exact="influenza" post="virus (60). This observation echoes the dilemma of producing"/>
 <result pre="it is possible that consecutive challenges with seasonal strains of" exact="influenza" post="will move the balance in favor of anti-head Abs."/>
 <result pre="the second most abundant glycoprotein on the surface of the" exact="influenza" post="virion. It is a homotetramer with a mushroom-like form,"/>
 <result pre="a short cytoplasmic N-terminal domain that is 100% homologous among" exact="influenza" post="strains, a transmembrane hydrophobic domain, and a stem-shaped C-terminal"/>
 <result pre="due to the central role that HA has played in" exact="influenza" post="research. However, for the last 50 years, important data"/>
 <result pre="gathered suggesting that anti-NA Abs can offer protection against the" exact="influenza" post="infection. In 1968, Schulman et al. demonstrated that Abs"/>
 <result pre="that anti-NA Abs were also present in humans after an" exact="influenza" post="infection (64). Later, Murphy et al. investigated the role"/>
 <result pre="variable levels of anti-NA Abs. These subjects were infected with" exact="influenza" post="virus A/NT/60/68 (H3N2), and the authors observed that the"/>
 <result pre="directly proportional to age, and their reactivity are highest against" exact="influenza" post="virus strains that more likely circulated during their childhood"/>
 <result pre="nasal secretions are independent predictors of immunity and protection to" exact="influenza" post="in samples taken pre and post pandemic of 2009"/>
 <result pre="and 21.2%, respectively. They also reported that after the 2007–2008" exact="influenza" post="season, NAI levels in subjects with confirmed infection rose"/>
 <result pre="with different recombinant NA resulted in reduction of mortality against" exact="influenza" post="virus challenges with heterologous (not heterosubtypic) strains. This protection"/>
 <result pre="of a &quot;universal vaccine,�? because it is highly conserved among" exact="influenza" post="strains, and because the capacity of anti-M2e Abs to"/>
 <result pre="this, such as coupling M2e to carrier proteins —like the" exact="hepatitis" post="B virus core protein (HBc) (102)— or to flagellin"/>
 <result pre="symptoms compared to group that received placebo, when challenged with" exact="influenza" post="virus A/Wisconsin/67/2005 (H3N2) (110). Also, several phase I and"/>
 <result pre="recently a phase I clinical trial started to evaluate a" exact="hepatitis" post="B core-M2e-based vaccine in Russia (NCT03789539) (113). Antibodies Against"/>
 <result pre="at least the anti-NP Abs can weakly help to clear" exact="influenza" post="infection (117, 118). The aa sequence of NP is"/>
 <result pre="NP is conserved up to 90%, among various strains of" exact="influenza" post="and heterosubtypic immunity (HSI) induced by this protein has"/>
 <result pre="shown that NP can be expressed on the surface of" exact="influenza" post="virus-infected cells (123–125), however evidence for Fc-mediated effector functions"/>
 <result pre="in human sera higher titers of NP-specific ADCC-Abs reactive to" exact="avian influenza" post="strain H7N9, as compared with HA- or NA-specific ADCC-Abs"/>
 <result pre="human sera higher titers of NP-specific ADCC-Abs reactive to avian" exact="influenza" post="strain H7N9, as compared with HA- or NA-specific ADCC-Abs"/>
 <result pre="Abs correlated with ADCC-Abs reactive to NP in the seasonal" exact="influenza" post="viruses (H1N1 and H3N2), suggesting that they could be"/>
 <result pre="received artificial IC consisting of a NP-specific mAb and the" exact="influenza" post="virus, the CTL response was restored, along with an"/>
 <result pre="experimental infected mice (114). A summary of protective Abs against" exact="influenza" post="virus and their mechanisms of protection is shown in"/>
 <result pre="respectively. Table 1 Mechanisms of action of protective antibodies against" exact="influenza" post="virus proteins in mouse and humans. Antibodies against Mechanism"/>
 <result pre="neutralizing and non-neutralizing Abs specific for different proteins of the" exact="influenza" post="virus. (A) Abs that neutralize the infection (B) Abs"/>
 <result pre="Nat Rev Microbiol. (2011) 9:590–603. 10.1038/nrmicro261321747392 3.YasudaJNakadaSKatoAToyodaTIshihamaA. Molecular assembly of" exact="influenza" post="virus: association of the NS2 protein with virion matrix."/>
 <result pre="novel interaction between the NS1 protein derived from the 1918" exact="influenza" post="virus and RIG-I. Structure. (2015) 23:2001–10. 10.1016/j.str.2015.08.00726365801 6.KlemmCBoergelingYLudwigSEhrhardtC. Immunomodulatory"/>
 <result pre="RIG-I. Structure. (2015) 23:2001–10. 10.1016/j.str.2015.08.00726365801 6.KlemmCBoergelingYLudwigSEhrhardtC. Immunomodulatory nonstructural proteins of" exact="influenza" post="A viruses. Trends Microbiol. (2018) 26:624-636. 10.1016/j.tim.2017.12.00629373257 7.ChenWCalvoPAMalideDGibbsJSchubertUBacikIet al.."/>
 <result pre="viruses. Trends Microbiol. (2018) 26:624-636. 10.1016/j.tim.2017.12.00629373257 7.ChenWCalvoPAMalideDGibbsJSchubertUBacikIet al.. A novel" exact="influenza" post="A virus mitochondrial protein that induces cell death. Nat"/>
 <result pre="Nat Immunol. (2006) 7:449–55. 10.1038/ni134316622432 9.CoxMMPatriarcaPATreanorJ. FluBlok, a recombinant hemagglutinin" exact="influenza" post="vaccine. Influenza Other Respir Viruses. (2008) 2:211–9. 10.1111/j.1750-2659.2008.00053.19453397 10.WongSSWebbyRJ."/>
 <result pre="Other Respir Viruses. (2008) 2:211–9. 10.1111/j.1750-2659.2008.00053.19453397 10.WongSSWebbyRJ. Traditional and new" exact="influenza" post="vaccines. Clin Microbiol Rev. (2013) 26:476–92. 10.1128/CMR.00097-1223824369 11.ChoiYSBaumgarthN. Dual"/>
 <result pre="10.1128/CMR.00097-1223824369 11.ChoiYSBaumgarthN. Dual role for B-1a cells in immunity to" exact="influenza" post="virus infection. J Exp Med. (2008) 205:3053–64. 10.1084/jem.2008097919075288 12.BaumgarthNHermanOCJagerGCBrownLEHerzenbergLAChenJ."/>
 <result pre="M antibodies are nonredundant components of the protective response to" exact="influenza" post="virus infection. J Exp Med. (2000) 192:271–80. 10.1084/jem.192.2.27110899913 13.BaumgarthN."/>
 <result pre="255:82–94. 10.1111/imr.1209423947349 14.JayasekeraJPMosemanEACarrollMC. Natural antibody and complement mediate neutralization of" exact="influenza" post="virus in the absence of prior immunity. J Virol."/>
 <result pre="J Virol. (2007) 81:3487–94. 10.1128/JVI.02128-0617202212 15.ChiuCEllebedyAHWrammertJAhmedR. B cell responses to" exact="influenza" post="infection and vaccination. Curr Top Microbiol Immunol. (2015) 386:381–98."/>
 <result pre="al.. CD4 T cell-independent antibody response promotes resolution of primary" exact="influenza" post="infection and helps to prevent reinfection. J Immunol. (2005)"/>
 <result pre="J Exp Med. (2000) 192:813–21. 10.1084/jem.192.6.81310993912 20.WangTTParidesMKPaleseP. Seroevidence for H5N1" exact="influenza" post="infections in humans: meta-analysis. Science. (2012) 335:1463. 10.1126/science.121888822362880 21.GaoRCaoBHuYFengZWangDHuWet"/>
 <result pre="335:1463. 10.1126/science.121888822362880 21.GaoRCaoBHuYFengZWangDHuWet al.. Human infection with a novel avian-origin" exact="influenza" post="A (H7N9) virus. N Engl J Med. (2013) 368:1888–97."/>
 <result pre="Med. (2013) 368:1888–97. 10.1056/NEJMoa130445923577628 22.CatonAJBrownleeGGYewdellJWGerhardW. The antigenic structure of the" exact="influenza" post="virus A/PR/8/34 hemagglutinin (H1 subtype). Cell. (1982) 31(2 Pt"/>
 <result pre="Pt 1):417–27. 10.1016/0092-8674(82)90135-06186384 23.LubeckMDGerhardW. Topological mapping antigenic sites on the" exact="influenza" post="A/PR/8/34 virus hemagglutinin using monoclonal antibodies. Virology. (1981) 113:64–72."/>
 <result pre="Annu Rev Microbiol. (1981) 35:185–206. 10.1146/annurev.mi.35.100181.0011536170247 25.GerhardWYewdellJFrankelMEWebsterR. Antigenic structure of" exact="influenza" post="virus haemagglutinin defined by hybridoma antibodies. Nature. (1981) 290:713–7."/>
 <result pre="viruses. Nat Immunol. (2017)18:456-463. 10.1038/ni.368028192417 27.LiuSTHBehzadiMASunWFreynAWLiuWCBroeckerFet al.. Antigenic sites in" exact="influenza" post="H1 hemagglutinin display species-specific immunodominance. J Clin Invest. (2018)"/>
 <result pre="antigenic site B in the hemagglutinin of the current H3N2" exact="influenza" post="virus in humans and mice. J Virol. (2018) 92:e01100-18."/>
 <result pre="29.SunWKangDSZhengALiuSTHBroeckerFSimonVet al.. Antibody responses toward the major antigenic sites of" exact="influenza" post="B virus hemagglutinin in mice, ferrets, and humans. J"/>
 <result pre="Hemagglutinin stalk- and neuraminidase-specific monoclonal antibodies protect against lethal H10N8" exact="influenza" post="virus infection in mice. J Virol. (2016) 90:851–61. 10.1128/JVI.02275-1526512088"/>
 <result pre="J Exp Med. (1966) 124:331–45. 10.1084/jem.124.3.3315922742 35.CobeySHensleySE. Immune history and" exact="influenza" post="virus susceptibility. Curr Opin Virol. (2017) 22:105–111. 10.1016/j.coviro.2016.12.00428088686 36.NdifonW."/>
 <result pre="Structural basis of preexisting immunity to the 2009 H1N1 pandemic" exact="influenza" post="virus. Science. (2010) 328:357–60. 10.1126/science.118643020339031 38.HancockKVeguillaVLuXZhongWButlerENSunHet al.. Cross-reactive antibody"/>
 <result pre="38.HancockKVeguillaVLuXZhongWButlerENSunHet al.. Cross-reactive antibody responses to the 2009 pandemic H1N1" exact="influenza" post="virus. N Engl J Med. (2009) 361:1945–52. 10.1056/NEJMoa090645319745214 39.KrauseJCTumpeyTMHuffmanCJMcGrawPAPearceMBTsibaneTet"/>
 <result pre="occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic" exact="influenza" post="A (H1N1) viruses. J Virol. (2010) 84:3127–30. 10.1128/JVI.02184-0920042511 40.LindermanSLHensleySE."/>
 <result pre="sin' properties are valuable components of secondary immune responses to" exact="influenza" post="viruses. PLoS Pathog. (2016) 12:e1005806. 10.1371/journal.ppat.100580627537358 41.WrammertJSmithKMillerJLangleyWAKokkoKLarsenCet al.. Rapid"/>
 <result pre="41.WrammertJSmithKMillerJLangleyWAKokkoKLarsenCet al.. Rapid cloning of high-affinity human monoclonal antibodies against" exact="influenza" post="virus. Nature. (2008) 453:667–71. 10.1038/nature0689018449194 42.O'DonnellCDet al.Humans and ferrets"/>
 <result pre="(2008) 453:667–71. 10.1038/nature0689018449194 42.O'DonnellCDet al.Humans and ferrets with prior H1N1" exact="influenza" post="virus infections do not exhibit evidence of original antigenic"/>
 <result pre="sin after infection or vaccination with the 2009 pandemic H1N1" exact="influenza" post="virus. Clin Vaccine Immunol. (2014) 21:737–46. 10.1128/CVI.00790-1324648486 43.YoshidaRIgarashiMOzakiHKishidaNTomabechiDKidaHet al.."/>
 <result pre="antibody directed against antigenic site B of the hemagglutinin of" exact="influenza" post="A viruses. PLoS Pathog. (2009) 5:e1000350. 10.1371/journal.ppat.100035019300497 44.WhittleJRZhangRKhuranaSKingLRManischewitzJGoldingHet al.."/>
 <result pre="Broadly neutralizing human antibody that recognizes the receptor-binding pocket of" exact="influenza" post="virus hemagglutinin. Proc Natl Acad Sci USA. (2011) 108:14216–21."/>
 <result pre="Acad Sci USA. (2011) 108:14216–21. 10.1073/pnas.111149710821825125 45.EkiertDCKashyapAKSteelJRubrumABhabhaGKhayatRet al.. Cross-neutralization of" exact="influenza" post="A viruses mediated by a single antibody loop. Nature."/>
 <result pre="Naturally occurring antibodies in humans can neutralize a variety of" exact="influenza" post="virus strains, including H3, H1, H2, and H5. J"/>
 <result pre="monoclonal antibody directed against a novel conserved epitope on the" exact="influenza" post="virus H3 hemagglutinin globular head. J Virol. (2014) 88:6743–50."/>
 <result pre="48.OkunoYIsegawaYSasaoFUedaS. A common neutralizing epitope conserved between the hemagglutinins of" exact="influenza" post="A virus H1 and H2 strains. J Virol. (1993)"/>
 <result pre="plasma cells that binds to group 1 and group 2" exact="influenza" post="A hemagglutinins. Science. (2011) 333:850–6. 10.1126/science.120566921798894 50.EkiertDCFriesenRHBhabhaGKwaksTJongeneelenMYuWet al.. A"/>
 <result pre="50.EkiertDCFriesenRHBhabhaGKwaksTJongeneelenMYuWet al.. A highly conserved neutralizing epitope on group 2" exact="influenza" post="A viruses. Science. (2011) 333:843–50. 10.1126/science.120483921737702 51.EkiertDCBhabhaGElsligerMAFriesenRHJongeneelenMThrosbyMet al.. Antibody"/>
 <result pre="333:843–50. 10.1126/science.120483921737702 51.EkiertDCBhabhaGElsligerMAFriesenRHJongeneelenMThrosbyMet al.. Antibody recognition of a highly conserved" exact="influenza" post="virus epitope. Science. (2009) 324:246–51. 10.1126/science.117149119251591 52.EkiertDCWilsonIA. Broadly neutralizing"/>
 <result pre="epitope. Science. (2009) 324:246–51. 10.1126/science.117149119251591 52.EkiertDCWilsonIA. Broadly neutralizing antibodies against" exact="influenza" post="virus and prospects for universal therapies. Curr Opin Virol."/>
 <result pre="Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against" exact="influenza" post="A viruses. PLoS Pathog. (2014) 10:e1004103. 10.1371/journal.ppat.100410324788925 54.AvnirYWatsonCTGlanvilleJPetersonECTallaricoASBennettASet al.IGHV1-69"/>
 <result pre="A broadly reactive human anti-hemagglutinin stem monoclonal antibody that inhibits" exact="influenza" post="A virus particle release. EBioMedicine. (2017) 17:182–91. 10.1016/j.ebiom.2017.03.00728286060 56.PalesePWangTT."/>
 <result pre="virus particle release. EBioMedicine. (2017) 17:182–91. 10.1016/j.ebiom.2017.03.00728286060 56.PalesePWangTT. Why do" exact="influenza" post="virus subtypes die out? A hypothesis. MBio. (2011) 2:5."/>
 <result pre="2:5. 10.1128/mBio.00150-1121878571 57.NachbagauerRChoiAHirshAMargineIIidaSBarreraAet al.Defining the antibody cross-reactome directed against the" exact="influenza" post="virus surface glycoproteins. Nat Immunol. (2017)8:464-473. 10.1038/ni.3684 58.Cortina-CeballosBGodoy-LozanoEETéllez-SosaJOvilla-MuñozMSámano-SánchezHAguilar-SalgadoAet al.."/>
 <result pre="cell repertoire reveals unique effects of immunization with a new" exact="influenza" post="virus strain. Genome Med. (2015) 7:124. 10.1186/s13073-015-0239-y26608341 59.LiGMChiuCWrammertJMcCauslandMAndrewsSFZhengNYet al.."/>
 <result pre="strain. Genome Med. (2015) 7:124. 10.1186/s13073-015-0239-y26608341 59.LiGMChiuCWrammertJMcCauslandMAndrewsSFZhengNYet al.. Pandemic H1N1" exact="influenza" post="vaccine induces a recall response in humans that favors"/>
 <result pre="Med. (2015) 7:316ra192. 10.1126/scitranslmed.aad052226631631 61.ChaiNSwemLRReicheltMChen-HarrisHLuisEParkSet al.. Two escape mechanisms of" exact="influenza" post="A virus to a broadly neutralizing stalk-binding antibody. PLoS"/>
 <result pre="63.SchulmanJLKhakpourMKilbourneED. Protective effects of specific immunity to viral neuraminidase on" exact="influenza" post="virus infection of mice. J Virol. (1968) 2:778–86.5701819 64.KilbourneEDChristensonWNSandeM."/>
 <result pre="J Virol. (1968) 2:778–86.5701819 64.KilbourneEDChristensonWNSandeM. Antibody response in man to" exact="influenza" post="virus neuraminidase following influenza. J Virol. (1968) 2:761–2.5723531 65.MurphyBRKaselJAChanockRM."/>
 <result pre="2:761–2.5723531 65.MurphyBRKaselJAChanockRM. Association of serum anti-neuraminidase antibody with resistance to" exact="influenza" post="in man. N Engl J Med. (1972) 286:1329–32. 10.1056/NEJM1972062228625025027388"/>
 <result pre="of antibody production against neuraminidase to the protection afforded by" exact="influenza" post="vaccines. Rev Med Virol. (2012) 22:267–79. 10.1002/rmv.171322438243 68.EichelbergerMCWanH. Influenza"/>
 <result pre="Immunol, 2015. 386: p. 275-99. 10.1007/82_2014_39825033754 69.MarcelinGBlandHMNegovetichNJSandbulteMREllebedyAHWebbADet al.. Inactivated seasonal" exact="influenza" post="vaccines increase serum antibodies to the neuraminidase of pandemic"/>
 <result pre="influenza vaccines increase serum antibodies to the neuraminidase of pandemic" exact="influenza" post="A(H1N1) 2009 virus in an age-dependent manner. J Infect"/>
 <result pre="influenza. Lancet. (1973) 1:623–5. 10.1016/S0140-6736(73)92196-X4121842 71.CoxRJ. Correlates of protection to" exact="influenza" post="virus where do we go from here?Hum Vaccin Immunother."/>
 <result pre="antihemagglutinin and antineuraminidase antibodies as correlates of protection in an" exact="influenza" post="A/H1N1 virus healthy human challenge model. MBio. (2016) 7:e00417–16."/>
 <result pre="al.. Antibody correlates and predictors of immunity to naturally occurring" exact="influenza" post="in humans and the importance of antibody to the"/>
 <result pre="J Infect Dis. (2013) 207:974–81. 10.1093/infdis/jis93523307936 74.MontoASPetrieJGCrossRTJohnsonELiuMZhongWet al.. Antibody to" exact="influenza" post="virus neuraminidase: an independent correlate of protection. J Infect"/>
 <result pre="recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against" exact="influenza" post="virus infection in mice. MBio. (2015) 6:e0255610.1128/mBio.02556-1425759506 76.SandbulteMRJimenezGSBoonACSmithLRTreanorJJWebbyRJ. Cross-reactive"/>
 <result pre="(2007) 4:e59. 10.1371/journal.pmed.004005917298168 77.Gillim-RossLSubbaraoK. Can immunity induced by the human" exact="influenza" post="virus N1 neuraminidase provide some protection from avian influenza"/>
 <result pre="the human influenza virus N1 neuraminidase provide some protection from" exact="avian influenza" post="H5N1 viruses?PLoS Med. (2007) 4:e91. 10.1371/journal.pmed.004009117298170 78.GérentesLKesslerNAymardM. Difficulties in"/>
 <result pre="human influenza virus N1 neuraminidase provide some protection from avian" exact="influenza" post="H5N1 viruses?PLoS Med. (2007) 4:e91. 10.1371/journal.pmed.004009117298170 78.GérentesLKesslerNAymardM. Difficulties in"/>
 <result pre="4:e91. 10.1371/journal.pmed.004009117298170 78.GérentesLKesslerNAymardM. Difficulties in standardizing the neuraminidase content of" exact="influenza" post="vaccines. Dev Biol Stand. (1999) 98:189–96; discussion 197.10494973 79.Getie-KebtieMSultanaIEichelbergerMAltermanM."/>
 <result pre="79.Getie-KebtieMSultanaIEichelbergerMAltermanM. Label-free mass spectrometry-based quantification of hemagglutinin and neuraminidase in" exact="influenza" post="virus preparations and vaccines. Influenza Other Respir Viruses. (2013)"/>
 <result pre="Influenza Other Respir Viruses. (2013) 7:521–30. 10.1111/irv.1200122943763 80.JohanssonBEKilbourneED. Dissociation of" exact="influenza" post="virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition."/>
 <result pre="their intravirionic antigenic competition. J Virol. (1993) 67:5721–3.8371337 81.JohanssonBEBucherDJKilbourneED. Purified" exact="influenza" post="virus hemagglutinin and neuraminidase are equivalent in stimulation of"/>
 <result pre="82.KrammerFFouchierRAMEichelbergerMCWebbyRJShaw-SalibaKWanHet al.. NAction! how can neuraminidase-based immunity contribute to better" exact="influenza" post="virus vaccines?MBio. (2018) 9:2. 10.1128/mBio.02332-1729615508 83.DiLilloDJPalesePWilsonPCRavetchJV. Broadly neutralizing anti-influenza"/>
 <result pre="neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against" exact="influenza" post="virus in vivo. Nat Med. (2014) 20:143–51. 10.1038/nm.344324412922 85.JegaskandaSLaurieKLAmarasenaTHWinnallWRKramskiMDe"/>
 <result pre="RoseRet al.. Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic" exact="influenza" post="A virus subtype H1N1. J Infect Dis. (2013) 208:1051–61."/>
 <result pre="Induction of H7N9-cross-reactive antibody-dependent cellular cytotoxicity antibodies by human seasonal" exact="influenza" post="A viruses that are directed toward the nucleoprotein. J"/>
 <result pre="High antibody-dependent cellular cytotoxicity antibody titers to H5N1 and H7N9" exact="avian influenza" post="A viruses in healthy US adults and older children."/>
 <result pre="antibody-dependent cellular cytotoxicity antibody titers to H5N1 and H7N9 avian" exact="influenza" post="A viruses in healthy US adults and older children."/>
 <result pre="212:1052–60. 10.1093/infdis/jiv18125795791 89.JegaskandaSReadingPCKentSJ. Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal" exact="influenza" post="vaccine. J Immunol. (2014) 193:469–75. 10.4049/jimmunol.140043224994909 90.Ana-Sosa-BatizFVandervenHJegaskandaSJohnstonARockmanSLaurieKet al.. Influenza-specific"/>
 <result pre="manner. MBio. (2016) 7:5. 10.1128/mBio.01624-1627703076 92.TerajimaMCruzJCoMDLeeJHKaurKWrammertJet al.. Complement-dependent lysis of" exact="influenza" post="a virus-infected cells by broadly cross-reactive human monoclonal antibodies."/>
 <result pre="Structure of the extracellular domain of matrix protein 2 of" exact="influenza" post="A virus in complex with a protective monoclonal antibody."/>
 <result pre="monoclonal antibody. J Virol. (2015) 89:3700–11. 10.1128/JVI.02576-1425609808 94.DengLChoKJFiersWSaelensX. M2e-based universal" exact="influenza" post="A vaccines. Vaccines. (2015) 3:105–36. 10.3390/vaccines301010526344949 95.ZebedeeSLLambRA. Influenza A"/>
 <result pre="96.TreanorJJTierneyELZebedeeSLLambRAMurphyBR. Passively transferred monoclonal antibody to the M2 protein inhibits" exact="influenza" post="A virus replication in mice. J Virol. (1990) 64:1375–7.2304147"/>
 <result pre="antibodies but plays a critical role in conferring protection after" exact="influenza" post="M2 vaccination. Immunology. (2014) 143:300–9. 10.1111/imm.1231024773389 98.El BakkouriKDescampsFDe FiletteMSmetAFestjensEBirkettAet"/>
 <result pre="Universal vaccine based on ectodomain of matrix protein 2 of" exact="influenza" post="A: Fc receptors and alveolar macrophages mediate protection. J"/>
 <result pre="al.. Therapeutic potential of a fully human monoclonal antibody against" exact="influenza" post="A virus M2 protein. Antiviral Res. (2008) 80:168–77. 10.1016/j.antiviral.2008.06.00218598723"/>
 <result pre="M2 protein. Antiviral Res. (2008) 80:168–77. 10.1016/j.antiviral.2008.06.00218598723 102.NeirynckSDerooTSaelensXVanlandschootPJouWMFiersW. A universal" exact="influenza" post="A vaccine based on the extracellular domain of the"/>
 <result pre="10.1038/1348410502819 103.TurleyCBRuppREJohnsonCTaylorDNWolfsonJTusseyLet al.. Safety and immunogenicity of a recombinant M2e-flagellin" exact="influenza" post="vaccine (STF2.4xM2e) in healthy adults. Vaccine. (2011) 29:5145–52. 10.1016/j.vaccine.2011.05.04121624416"/>
 <result pre="to gold nanoparticles confers protection against H1N1, H3N2 and H5N1" exact="influenza" post="A viruses. Antiviral Res. (2017) 141:62–72. 10.1016/j.antiviral.2017.01.02128161578 105.GaoXWangWLiYZhangSDuanYXingLet al.."/>
 <result pre="10.1016/j.antiviral.2013.01.01023416215 106.TompkinsSMZhaoZSLoCYMisplonJALiuTYeZet al.. Matrix protein 2 vaccination and protection against" exact="influenza" post="viruses, including subtype H5N1. Emerg Infect Dis. (2007) 13:426–35."/>
 <result pre="Dis. (2007) 13:426–35. 10.3201/eid1303.06112517552096 107.KimYJKoEJKimMCLeeYNKimKHJungYJet al.. Roles of antibodies to" exact="influenza" post="A virus hemagglutinin, neuraminidase, and M2e in conferring cross"/>
 <result pre="to matrix protein 2 following natural infection with 2009 pandemic" exact="influenza" post="A(H1N1) virus in humans. J Infect Dis. (2014) 209:986–94.24325965"/>
 <result pre="(accesed November 13, 2017). 113.TsybalovaLMStepanovaLAKuprianovVVBlokhinaEAPotapchukMVKorotkovAVet al.. Development of a candidate" exact="influenza" post="vaccine based on virus-like particles displaying influenza M2e peptide"/>
 <result pre="of a candidate influenza vaccine based on virus-like particles displaying" exact="influenza" post="M2e peptide into the immunodominant region of hepatitis B"/>
 <result pre="particles displaying influenza M2e peptide into the immunodominant region of" exact="hepatitis" post="B core antigen: Broad protective efficacy of particles carrying"/>
 <result pre="al.. Antibodies to PB1-F2 protein are induced in response to" exact="influenza" post="A virus infection. Arch Virol. (2009) 154:1599–604. 10.1007/s00705-009-0479-519672555 115.KhuranaSChungKYCoyleEMMeijerAGoldingH."/>
 <result pre="antibody response in humans following exposure to highly pathogenic H7N7" exact="avian influenza" post="virus: evidence for Anti-PA-X antibodies. J Virol. (2016) 90:9383–93."/>
 <result pre="response in humans following exposure to highly pathogenic H7N7 avian" exact="influenza" post="virus: evidence for Anti-PA-X antibodies. J Virol. (2016) 90:9383–93."/>
 <result pre="antibody dependent natural killer cell activation by antibodies to internal" exact="influenza" post="virus proteins. EBioMedicine. (2016) 8:277–90. 10.1016/j.ebiom.2016.04.02927428437 117.LaMereMWLamHTMoquinAHaynesLLundFERandallTDet al.. Contributions"/>
 <result pre="117.LaMereMWLamHTMoquinAHaynesLLundFERandallTDet al.. Contributions of antinucleoprotein IgG to heterosubtypic immunity against" exact="influenza" post="virus. J Immunol. (2011) 186:4331–9. 10.4049/jimmunol.100305721357542 118.CarragherDMKaminskiDAMoquinAHartsonLRandallTD. A novel"/>
 <result pre="role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to" exact="influenza" post="virus. J Immunol. (2008) 181:4168–76. 10.4049/jimmunol.181.6.416818768874 119.ShuLLBeanWJWebsterRG. Analysis of"/>
 <result pre="119.ShuLLBeanWJWebsterRG. Analysis of the evolution and variation of the human" exact="influenza" post="A virus nucleoprotein gene from 1933 to 1990. J"/>
 <result pre="122.Rangel-MorenoJCarragherDMMisraRSKusserKHartsonLMoquinAet al.. B cells promote resistance to heterosubtypic strains of" exact="influenza" post="via multiple mechanisms. J Immunol. (2008) 180:454–63. 10.4049/jimmunol.180.1.45418097047 123.YewdellJWFrankEGerhardW."/>
 <result pre="multiple mechanisms. J Immunol. (2008) 180:454–63. 10.4049/jimmunol.180.1.45418097047 123.YewdellJWFrankEGerhardW. Expression of" exact="influenza" post="A virus internal antigens on the surface of infected"/>
 <result pre="immunological significance of a human monoclonal antibody directed to the" exact="influenza" post="a virus nucleoprotein. Clin Vaccine Immunol. (2013) 20:1333–7. 10.1128/CVI.00339-1323761662"/>
 <result pre="10.1128/CVI.00339-1323761662 125.VirelizierJLAllisonACOxfordJSSchildGC. Early presence of ribonucleoprotein antigen on surface of" exact="influenza" post="virus-infected cells. Nature. (1977) 266:52–4. 10.1038/266052a0840296 126.LeónBBallesteros-TatoARandallTDLundFE. Prolonged antigen"/>
 <result pre="Rectification of age-associated deficiency in cytotoxic T cell response to" exact="influenza" post="A virus by immunization with immune complexes. J Immunol."/>
</results>
